Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers.
Praharaj M, Shen F, Lee AJ, Zhao L, Nirschl TR, Theodros D, Singh AK, Wang X, Adusei KM, Lombardo KA, Williams RA, Sena LA, Thompson EA, Tam A, Yegnasubramanian S, Pearce EJ, Leone RD, Alt J, Rais R, Slusher BS, Pardoll DM, Powell JD, Zarif JC. Praharaj M, et al. Among authors: yegnasubramanian s. Cancer Immunol Res. 2024 Jul 2;12(7):854-875. doi: 10.1158/2326-6066.CIR-23-1105. Cancer Immunol Res. 2024. PMID: 38701369 Free PMC article.
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. Ribas J, et al. Among authors: yegnasubramanian s. Cancer Res. 2009 Sep 15;69(18):7165-9. doi: 10.1158/0008-5472.CAN-09-1448. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738047 Free PMC article.
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Hu R, et al. Among authors: yegnasubramanian s. Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18. Cancer Res. 2012. PMID: 22710436 Free PMC article.
Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.
Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S. Haffner MC, et al. Among authors: yegnasubramanian s. Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8580-E8582. doi: 10.1073/pnas.1803292115. Epub 2018 Sep 4. Proc Natl Acad Sci U S A. 2018. PMID: 30181298 Free PMC article. No abstract available.
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, McKiernan E, Yegnasubramanian S, Drake CG. Mao W, et al. Among authors: yegnasubramanian s. J Immunother Cancer. 2019 Oct 25;7(1):277. doi: 10.1186/s40425-019-0758-y. J Immunother Cancer. 2019. PMID: 31653272 Free PMC article.
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG. Freeman ZT, et al. Among authors: yegnasubramanian s. J Clin Invest. 2020 Mar 2;130(3):1405-1416. doi: 10.1172/JCI128672. J Clin Invest. 2020. PMID: 32015231 Free PMC article.
Metabolic programs define dysfunctional immune responses in severe COVID-19 patients.
Thompson EA, Cascino K, Ordonez AA, Zhou W, Vaghasia A, Hamacher-Brady A, Brady NR, Sun IH, Wang R, Rosenberg AZ, Delannoy M, Rothman R, Fenstermacher K, Sauer L, Shaw-Saliba K, Bloch EM, Redd AD, Tobian AA, Horton M, Smith K, Pekosz A, D'Alessio FR, Yegnasubramanian S, Ji H, Cox AL, Powell JD. Thompson EA, et al. Among authors: yegnasubramanian s. medRxiv [Preprint]. 2020 Oct 5:2020.09.10.20186064. doi: 10.1101/2020.09.10.20186064. medRxiv. 2020. Update in: Cell Rep. 2021 Mar 16;34(11):108863. doi: 10.1016/j.celrep.2021.108863 PMID: 32935120 Free PMC article. Updated. Preprint.
Metabolic programs define dysfunctional immune responses in severe COVID-19 patients.
Thompson EA, Cascino K, Ordonez AA, Zhou W, Vaghasia A, Hamacher-Brady A, Brady NR, Sun IH, Wang R, Rosenberg AZ, Delannoy M, Rothman R, Fenstermacher K, Sauer L, Shaw-Saliba K, Bloch EM, Redd AD, Tobian AAR, Horton M, Smith K, Pekosz A, D'Alessio FR, Yegnasubramanian S, Ji H, Cox AL, Powell JD. Thompson EA, et al. Among authors: yegnasubramanian s. Cell Rep. 2021 Mar 16;34(11):108863. doi: 10.1016/j.celrep.2021.108863. Epub 2021 Feb 26. Cell Rep. 2021. PMID: 33691089 Free PMC article.
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses.
Dykema AG, Zhang B, Woldemeskel BA, Garliss CC, Cheung LS, Choudhury D, Zhang J, Aparicio L, Bom S, Rashid R, Caushi JX, Hsiue EH, Cascino K, Thompson EA, Kwaa AK, Singh D, Thapa S, Ordonez AA, Pekosz A, D'Alessio FR, Powell JD, Yegnasubramanian S, Zhou S, Pardoll DM, Ji H, Cox AL, Blankson JN, Smith KN. Dykema AG, et al. Among authors: yegnasubramanian s. J Clin Invest. 2021 May 17;131(10):e146922. doi: 10.1172/JCI146922. J Clin Invest. 2021. PMID: 33830946 Free PMC article.
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.
Sidiropoulos DN, Rafie CI, Jang JK, Castanon S, Baugh AG, Gonzalez E, Christmas BJ, Narumi VH, Davis-Marcisak EF, Sharma G, Bigelow E, Vaghasia A, Gupta A, Skaist A, Considine M, Wheelan SJ, Ganesan SK, Yu M, Yegnasubramanian S, Stearns V, Connolly RM, Gaykalova DA, Kagohara LT, Jaffee EM, Fertig EJ, Roussos Torres ET. Sidiropoulos DN, et al. Among authors: yegnasubramanian s. Cancer Immunol Res. 2022 May 3;10(5):656-669. doi: 10.1158/2326-6066.CIR-21-0170. Cancer Immunol Res. 2022. PMID: 35201318 Free PMC article.
174 results